Q1 EARNINGS: Thoratec hopeful for the future
This article was originally published in Clinica
Heart assist device specialist Thoratec saw its top and bottom lines fall in Q1, but it still exceeded analyst expectations and consequently improved its sales and earnings outlook for the year. Q1 sales of $121.3m shrank 4% as reported, but came in ahead of consensus of $109.8m. Revenues also grew 4% at constant currency rates and excluding Japan, “where unusual order patterns impact reported growth,” according to the company.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.